Cargando…

Harnessing immunological targets for COVID-19 immunotherapy

COVID-19 is an infectious and highly contagious disease caused by SARS-CoV-2. The immunotherapy strategy has a great potential to develop a permanent cure against COVID-19. Innate immune cells are in constant motion to scan molecular alteration to cells led by microbial infections throughout the bod...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehata, Abhishesh Kumar, Viswanadh, Matte Kasi, Priya, Vishnu, , Vikas, Muthu, Madaswamy S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375415/
https://www.ncbi.nlm.nih.gov/pubmed/34447458
http://dx.doi.org/10.2217/fvl-2021-0048
_version_ 1783740310510108672
author Mehata, Abhishesh Kumar
Viswanadh, Matte Kasi
Priya, Vishnu
, Vikas
Muthu, Madaswamy S
author_facet Mehata, Abhishesh Kumar
Viswanadh, Matte Kasi
Priya, Vishnu
, Vikas
Muthu, Madaswamy S
author_sort Mehata, Abhishesh Kumar
collection PubMed
description COVID-19 is an infectious and highly contagious disease caused by SARS-CoV-2. The immunotherapy strategy has a great potential to develop a permanent cure against COVID-19. Innate immune cells are in constant motion to scan molecular alteration to cells led by microbial infections throughout the body and helps in clearing invading viruses. Harnessing immunological targets for removing viral infection, generally based on the principle of enhancing the T-cell and protective immune responses. Currently-approved COVID-19 vaccines are mRNA encapsulated in liposomes that stimulate the host immune system to produce antibodies. Given the vital role of innate immunity, harnessing these immune responses opens up new hope for the generation of long-lasting and protective immunity against COVID-19.
format Online
Article
Text
id pubmed-8375415
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-83754152021-08-24 Harnessing immunological targets for COVID-19 immunotherapy Mehata, Abhishesh Kumar Viswanadh, Matte Kasi Priya, Vishnu , Vikas Muthu, Madaswamy S Future Virol Review COVID-19 is an infectious and highly contagious disease caused by SARS-CoV-2. The immunotherapy strategy has a great potential to develop a permanent cure against COVID-19. Innate immune cells are in constant motion to scan molecular alteration to cells led by microbial infections throughout the body and helps in clearing invading viruses. Harnessing immunological targets for removing viral infection, generally based on the principle of enhancing the T-cell and protective immune responses. Currently-approved COVID-19 vaccines are mRNA encapsulated in liposomes that stimulate the host immune system to produce antibodies. Given the vital role of innate immunity, harnessing these immune responses opens up new hope for the generation of long-lasting and protective immunity against COVID-19. Future Medicine Ltd 2021-08-09 2021-07 /pmc/articles/PMC8375415/ /pubmed/34447458 http://dx.doi.org/10.2217/fvl-2021-0048 Text en © 2021 Future Medicine Ltd https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review
Mehata, Abhishesh Kumar
Viswanadh, Matte Kasi
Priya, Vishnu
, Vikas
Muthu, Madaswamy S
Harnessing immunological targets for COVID-19 immunotherapy
title Harnessing immunological targets for COVID-19 immunotherapy
title_full Harnessing immunological targets for COVID-19 immunotherapy
title_fullStr Harnessing immunological targets for COVID-19 immunotherapy
title_full_unstemmed Harnessing immunological targets for COVID-19 immunotherapy
title_short Harnessing immunological targets for COVID-19 immunotherapy
title_sort harnessing immunological targets for covid-19 immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375415/
https://www.ncbi.nlm.nih.gov/pubmed/34447458
http://dx.doi.org/10.2217/fvl-2021-0048
work_keys_str_mv AT mehataabhisheshkumar harnessingimmunologicaltargetsforcovid19immunotherapy
AT viswanadhmattekasi harnessingimmunologicaltargetsforcovid19immunotherapy
AT priyavishnu harnessingimmunologicaltargetsforcovid19immunotherapy
AT vikas harnessingimmunologicaltargetsforcovid19immunotherapy
AT muthumadaswamys harnessingimmunologicaltargetsforcovid19immunotherapy